Kazia CEO Dr James Garner said: “The R&D tax rebate is entirely consistent with our forecasts.
“Both GDC-0084 and Cantrixil have had important and value-driving data read-outs during calendar 2019, and the R&D tax rebate will be directly applied to generating further progress in these programs.
“We anticipate further data read-outs in calendar 2020, along with transition of GDC-0084 into a pivotal study for FDA registration.”
GDC-0084 data expected in 1H 2020
GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018.
Interim data was reported in November 2019, and further data is expected in 1H 2020.